Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 17/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22764036 | 1.00 | ADRB2 (0.50) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL22764031 | 0.85 | MAPT (0.50) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL14291852 | 0.72 | ADRB2 (0.62) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL19236388 | 0.72 | ADRB2 (0.62) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL1311067 | 0.72 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL2852257 | 0.72 | ADRB2 (0.67) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL7152531 | 0.72 | ADRB2 (0.67) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL6462710 | 0.72 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL1311066 | 0.72 | ADRB2 (0.59) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| SCHEMBL22763954 | 0.70 | SMN1; SMN2 (0.52) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | OLON S.P.A. (IT) | 2021-07-06 | — | — | US | disclosed |
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | OLON S.P.A. (IT) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385366-A1 | PROCESS FOR PREPARING INTERMEDIATES FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS BY ENZYMATIC REDUCTION AND NOVEL SYNTHESIS INTERMEDIATES | ADH1A, ADH1C, ADH5 | ADRB2 416/4885ADRB1 233/4885CYP1A2 37/4885 |
| US-11053227-B2 | Process for preparing intermediates for the synthesis of optically active beta-amino alcohols by enzymatic reduction and novel synthesis intermediates | ADH1A, ADH1C, ADH5 | ADRB2 416/4885ADRB1 233/4885CYP1A2 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.